Mark D. Hjelmeland
- Co-authors
- Jeremy N. RichDarell D. BignerHenry S. FriedmanAnita B. HjelmelandNicholas J. LapingMichael H. HerbstreithSith SathornsumeteeQing Shi
- Topics
- TGF-β signaling in diseases (4 papers)Angiogenesis and VEGF in Cancer (2 papers)Immune Cell Function and Interaction (2 papers)
- Cited by
- GeneticsCancer ResearchOncology
- Partner nations
- United StatesBulgariaCanada
In The Last Decade
Mark D. Hjelmeland
8 papers receiving 772 citations
Peers
Comparison fields: 5 of 67
- Molecular Biology 543
- Oncology 246
- Genetics 160
- Cancer Research 144
- Pathology and Forensic Medicine 103
Countries citing papers authored by Mark D. Hjelmeland
This map shows the geographic impact of Mark D. Hjelmeland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Hjelmeland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Hjelmeland more than expected).
Fields of papers citing papers by Mark D. Hjelmeland
This network shows the impact of papers produced by Mark D. Hjelmeland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Hjelmeland. The network helps show where Mark D. Hjelmeland may publish in the future.
Co-authorship network of co-authors of Mark D. Hjelmeland
This figure shows the co-authorship network connecting the top 25 collaborators of Mark D. Hjelmeland. A scholar is included among the top collaborators of Mark D. Hjelmeland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark D. Hjelmeland. Mark D. Hjelmeland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 32 | |
| 2 | 33 | |
| 3 | 192 | |
| 4 | 158 | |
| 5 | SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. | 168 |
| 6 | 132 | |
| 7 | 65 | |
| 8 | 2 |
About Mark D. Hjelmeland
Mark D. Hjelmeland is a scholar working on Immunology and Allergy, Molecular Biology and Immunology, having authored 8 papers that have together received 782 indexed citations. Recurring topics across this work include TGF-β signaling in diseases (4 papers), Angiogenesis and VEGF in Cancer (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Genetics (160 citations), Cancer Research (144 citations) and Oncology (246 citations). Mark D. Hjelmeland has collaborated with scholars based in United States, Bulgaria and Canada. Frequent co-authors include Jeremy N. Rich, Darell D. Bigner, Henry S. Friedman, Anita B. Hjelmeland, Nicholas J. Laping, Michael H. Herbstreith, Sith Sathornsumetee, Qing Shi, Thomas J. Cummings and Qing Shi. Their work appears in journals such as Journal of Biological Chemistry, Cancer Research and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.